Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study

Shoou-Chern Li; Youngmi Wang; 최성진; Yeon Soo Jung; 한경희; 정인배; Lee San hui

Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study

Recommendations

Search

Type: Academic journal

Author: Shoou-Chern Li Youngmi Wang 최성진 Yeon Soo Jung 한경희 정인배 Lee San hui

Journal: Korean Society of Obstetrics and Gynecology Obstetrics & Gynecology Science Obstetrics & Gynecology Science 제62권 제5호 KCI Accredited Journals

Published: 2019.1

Pages: 344 - 351 (8page)

Usage

Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study

Abstract· Keywords

Report Errors

ObjectiveThe purpose of this study was to evaluate the effectiveness of scheduled ramosetron injections for controllingpostoperative nausea and vomiting (PONV) after single-port access total laparoscopic hysterectomy (SPA-TLH). MethodsNinety patients who underwent SPA-TLH at the Korean National Health Insurance Service Ilsan Hospital between June2013 and July 2014 were enrolled in this prospective, randomized, double-blinded, placebo-controlled study. Thepatients were divided into 2 groups as follows: the ramosetron group (0.3 mg intravenously [IV]; n=45) and the placebogroup (normal saline IV; n=45). Both groups received their respective injections 12 and 24 hours post surgery. Theincidence and severity of PONV (numerical rating scale, 0–10), and the use of rescue antiemetics post surgery wereevaluated. ResultsDemographic and perioperative statistically significant differences were not observed between the 2 groups. Theincidence of PONV in the ramosetron and placebo groups was 46.7% and 51.1%, respectively (P=0.51). We foundsignificant differences in the severity of PONV between the 24- to 48-hour postoperative periods in both groups(ramosetron group, P=0.04 and placebo group, P=0.03). The use of rescue antiemetics was significantly lower in theramosetron group than in the placebo group (P=0.02). ConclusionAfter general anesthesia, scheduled injections of ramosetron 12 and 24 hours after SPA-TLH reduced the severity ofPONV and the use of rescue antiemetics. Administration of ramosetron can be considered not only immediately afterSPA-TLH but also during the first 24-hour recovery period. Trial RegistrationClinicalTrials.gov Identifier: NCT 02011659

No content found

References (24)

Add References

Macario A / 1999 / Which clinical anesthesia outcomes are important to avoid? The perspective of patients / Anesth Analg 89:652~658

Gan TJ / 2003 / Consensus guidelines for managing postoperative nausea and vomiting / Anesth Analg 97:62~71

Rowbotham D / 1995 / Recognising risk factors / Nurs Times 91:44~46

Stadler M / 2003 / Difference in risk factors for postoperative nausea and vomiting / Anesthesiology 98:46~52

Jacobson TZ / 2004 / Safe laparoscopy : is it possible / Curr Opin Obstet Gynecol 16:283~288

Recommendations

It is an article recommended by DBpia according to the article similarity. Check out the related articles!